These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7791071)

  • 1. RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat.
    Pendley CE; Fitzpatrick LR; Capolino AJ; Davis MA; Esterline NJ; Jakubowska A; Bertrand P; Guyon C; Dubroeucq MC; Martin GE
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1015-22. PubMed ID: 7791071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.
    Nishida A; Takinami Y; Yuki H; Kobayashi A; Akuzawa S; Kamato T; Ito H; Yamano M; Nagakura Y; Miyata K
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1256-61. PubMed ID: 7932178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists.
    Bertrand P; Böhme GA; Durieux C; Guyon C; Capet M; Jeantaud B; Boudeau P; Ducos B; Pendley CE; Martin GE
    Eur J Pharmacol; 1994 Sep; 262(3):233-45. PubMed ID: 7813588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat.
    Pendley CE; Fitzpatrick LR; Ewing RW; Molino BF; Martin GE
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1348-54. PubMed ID: 8510013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist.
    Makovec F; Revel L; Letari O; Mennuni L; Impicciatore M
    Eur J Pharmacol; 1999 Mar; 369(1):81-90. PubMed ID: 10204685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl] urea with potent gastric mucosal protective activity on acute gastric lesions and duodenal ulcers in rats.
    Sekiguchi H; Hamada K; Taga F; Nishino K
    Arzneimittelforschung; 1993 Feb; 43(2):134-8. PubMed ID: 8096133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of N-(3-[3-(1-piperidinylmethyl)phenoxy]propyl)-acetoxyacetamide hydrochloride (TZU-0460), a histamine H2-receptor antagonist, on gastric acid secretion and ulcer formation.
    Tarutani M; Sakuma H; Shiratsuchi K; Mieda M
    Arzneimittelforschung; 1985; 35(5):844-8. PubMed ID: 2862875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-antigastrin activity relationships of new spiroglumide amido acid derivatives.
    Makovec F; Peris W; Frigerio S; Giovanetti R; Letari O; Mennuni L; Revel L
    J Med Chem; 1996 Jan; 39(1):135-42. PubMed ID: 8568800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors. II.
    Takeda Y; Kawagoe K; Yokomizo A; Yokomizo Y; Hosokami T; Shimoto Y; Tabuchi Y; Ogihara Y; Otsubo R; Honda Y; Yokohama S
    Chem Pharm Bull (Tokyo); 1998 Jun; 46(6):951-61. PubMed ID: 9658573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.
    Takinami Y; Yuki H; Nishida A; Akuzawa S; Uchida A; Takemoto Y; Ohta M; Satoh M; Semple G; Miyata K
    Aliment Pharmacol Ther; 1997 Feb; 11(1):113-20. PubMed ID: 9042983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
    Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD
    Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of capsaicin-sensitive afferent nerves and cholecystokinin 2/gastrin receptors in gastroprotection and adaptation of gastric mucosa to Helicobacter pylori-lipopolysaccharide.
    Brzozowski T; Konturek PC; Moran AP; Pajdo R; Kwiecien S; Konturek SJ; Sliwowski Z; Drozdowicz D; Pawlik WW; Hahn EG
    J Pharmacol Exp Ther; 2004 Jul; 310(1):116-25. PubMed ID: 15024038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the variation in the action of L-365,260 at CCKB/gastrin receptors in rat, guinea-pig and mouse isolated gastric tissue assays.
    Roberts SP; Harper EA; Watt GF; Gerskowitch VP; Hull RA; Shankley NP; Black JW
    Br J Pharmacol; 1996 Aug; 118(7):1779-89. PubMed ID: 8842444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stomach-brain communication by vagal afferents in response to luminal acid backdiffusion, gastrin, and gastric acid secretion.
    Danzer M; Jocic M; Samberger C; Painsipp E; Bock E; Pabst MA; Crailsheim K; Schicho R; Lippe IT; Holzer P
    Am J Physiol Gastrointest Liver Physiol; 2004 Mar; 286(3):G403-11. PubMed ID: 14592947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a gastrin/cholecystokinin B receptor antagonist, S-0509, on the omeprazole-induced proliferation of gastric mucosa in rats.
    Ono M; Sato H; Kazumori H; Yuki M; Rumi MA; Ortega-Cava CF; Ishihara Y; Ishihara S; Adachi K; Kinoshita Y
    J Lab Clin Med; 2003 Dec; 142(6):364-71. PubMed ID: 14713888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of S-0509, a novel CCKB/gastrin receptor antagonist, on acid secretion and experimental duodenal ulcers in rats.
    Takeuchi K; Hirata T; Yamamoto H; Kunikata T; Ishikawa M; Ishihara Y
    Aliment Pharmacol Ther; 1999 Jan; 13(1):87-96. PubMed ID: 9892884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the specificity and potency of a series of cholecystokinin-B/gastrin receptor antagonists in vivo.
    Ding XQ; Håkanson R
    Pharmacol Toxicol; 1996 Sep; 79(3):124-30. PubMed ID: 8884870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors. III.
    Takeda Y; Kawagoe K; Yokomizo A; Yokomizo Y; Hosokami T; Shimoto Y; Tabuchi Y; Ogihara Y; Honda Y; Kawarabayashi K; Iseri M; Yokohama S
    Chem Pharm Bull (Tokyo); 1999 Jun; 47(6):755-71. PubMed ID: 10399834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healing-promoting action of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl]urea with dual action on chronic gastric and duodenal ulcers induced by acetic acid in rats.
    Sekiguchi H; Hamada K; Aijima H; Taga F; Uchida H; Nishino K
    Arzneimittelforschung; 1993 Feb; 43(2):139-43. PubMed ID: 8096134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholecystokinin stimulates ascorbic acid secretion through its specific receptor in the perfused stomach of rats.
    Muto N; Eguchi R; Akagi Y; Itoh N; Tanaka K
    Res Commun Mol Pathol Pharmacol; 1998 Aug; 101(2):127-36. PubMed ID: 9821209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.